This bill prohibits health insurers and contracted entities that provide pharmacy benefits management services from receiving a price reduction or other remuneration from prescription drug manufacturers. The prohibition does not apply if (1) the price reduction is reflected at the point-of-sale; and (2) the other remuneration is a transparent, flat service fee that the manufacturer pays in relation to pharmacy benefits management services.